Skip to main content
NVDA+0.10%AAPL-0.10%GOOGL-1.24%MSFT0.00%AMZN+0.25%TSM+1.49%SPCX+1.89%META-0.36%AVGO-0.48%TSLA-0.14%LLY-2.54%BRK-B-0.87%MU+0.09%SKHY+4.05%WMT-1.02%JPM-1.47%AMD+1.74%V-1.55%XOM+2.79%JNJ-1.42%ASMLa-0.87%MA-1.52%ABBV+0.16%CVX+2.88%INTC+1.72%0700.HK+0.94%COST-1.46%1398.HK-1.50%CSCO+1.53%KO-2.76%ORCL+0.49%UNH-1.62%PG-2.76%BAC-1.02%1816.HK+0.44%3988.HK-0.50%HD-2.41%CAT-2.42%0005.HK-1.04%PM-1.13%HSBA.L-1.07%AP2d-0.03%0857.HK-0.93%0939.HK+0.51%AMAT+0.44%GE-2.69%1288.HK-1.94%DELL+0.77%LRCX-0.02%NVS-3.30%GBPTRY+0.41%EURCAD+0.39%GBPHKD+0.32%GBPMXN-0.28%CADCHF-0.28%EURJPY+0.26%AUDCAD+0.23%USDCAD+0.23%USDTHB-0.23%NZDCAD+0.20%CHFJPY+0.17%EURGBP+0.17%USDILS+0.16%EURNZD+0.16%GBPCAD+0.15%EURUSD+0.15%EURAUD+0.13%AUDJPY+0.12%CADJPY-0.11%EURCHF+0.10%USDJPY+0.09%GBPCHF-0.09%NZDJPY+0.08%NZDCHF-0.07%USDTRY+0.06%GBPJPY+0.05%GBPAUD-0.05%USDCHF-0.05%NZDUSD-0.04%USDCOP-0.04%AUDCHF-0.03%USDCNH+0.03%AUDNZD+0.03%AUDUSD+0.02%GBPUSD-0.02%GBPNZD+0.01%USDHKD+0.01%USDZAR0.00%USDSEK0.00%USDDKK0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURDKK0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURSGD0.00%EURSEK0.00%GBPZAR0.00%GBPSGD0.00%NZDMXN0.00%PLNJPY0.00%EURNOK0.00%NZDSGD0.00%EURPLN0.00%EURCZK0.00%NOKJPY0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%CHFNOK0.00%USDMXN0.00%USDNOK0.00%USDPLN0.00%GAGUSD0.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%W10.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-0.36%ETHUSD+22.11%USDTUSD+0.02%XRPUSD+15.55%SOLUSD+15.78%TRXUSDT+0.46%ZECUSDT-0.01%DOGEUSD+20.76%XMRUSDT-2.44%LINKUSD+23.15%BCHUSDT+1.02%XLMUSD-1.73%UNIUSD+1.50%LTCUSD+17.32%SUIUSD-1.49%HBARUSDT-0.65%TONUSD+36.45%TAOUSDT+0.91%AAVEUSD-0.74%DOTUSDT-1.43%ICPUSDT-1.29%ONDOUSDT-0.76%WLDUSDT-3.10%ARBUSDT+0.08%JUPUSDT-2.64%ATOMUSDT+0.17%INJUSDT+2.64%STXUSDT-0.43%TIAUSDT-0.56%PYTHUSDT+5.34%FETUSDT-2.19%SEIUSDT-3.15%IMXUSDT-1.76%GRTUSDT-2.00%OPUSDT-1.73%IOTAUSDT-2.01%WIFUSDT-4.11%POLUSDT-0.02%AXSUSDT-1.91%EOSUSDT-3.12%FARTCOINUSDT-2.60%DYDXUSDT-3.01%GALAUSDT-2.36%ORDIUSDT-1.50%RONINUSDT-1.68%NOTUSDT-1.33%NVDA+0.10%AAPL-0.10%GOOGL-1.24%MSFT0.00%AMZN+0.25%TSM+1.49%SPCX+1.89%META-0.36%AVGO-0.48%TSLA-0.14%LLY-2.54%BRK-B-0.87%MU+0.09%SKHY+4.05%WMT-1.02%JPM-1.47%AMD+1.74%V-1.55%XOM+2.79%JNJ-1.42%ASMLa-0.87%MA-1.52%ABBV+0.16%CVX+2.88%INTC+1.72%0700.HK+0.94%COST-1.46%1398.HK-1.50%CSCO+1.53%KO-2.76%ORCL+0.49%UNH-1.62%PG-2.76%BAC-1.02%1816.HK+0.44%3988.HK-0.50%HD-2.41%CAT-2.42%0005.HK-1.04%PM-1.13%HSBA.L-1.07%AP2d-0.03%0857.HK-0.93%0939.HK+0.51%AMAT+0.44%GE-2.69%1288.HK-1.94%DELL+0.77%LRCX-0.02%NVS-3.30%GBPTRY+0.41%EURCAD+0.39%GBPHKD+0.32%GBPMXN-0.28%CADCHF-0.28%EURJPY+0.26%AUDCAD+0.23%USDCAD+0.23%USDTHB-0.23%NZDCAD+0.20%CHFJPY+0.17%EURGBP+0.17%USDILS+0.16%EURNZD+0.16%GBPCAD+0.15%EURUSD+0.15%EURAUD+0.13%AUDJPY+0.12%CADJPY-0.11%EURCHF+0.10%USDJPY+0.09%GBPCHF-0.09%NZDJPY+0.08%NZDCHF-0.07%USDTRY+0.06%GBPJPY+0.05%GBPAUD-0.05%USDCHF-0.05%NZDUSD-0.04%USDCOP-0.04%AUDCHF-0.03%USDCNH+0.03%AUDNZD+0.03%AUDUSD+0.02%GBPUSD-0.02%GBPNZD+0.01%USDHKD+0.01%USDZAR0.00%USDSEK0.00%USDDKK0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURDKK0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURSGD0.00%EURSEK0.00%GBPZAR0.00%GBPSGD0.00%NZDMXN0.00%PLNJPY0.00%EURNOK0.00%NZDSGD0.00%EURPLN0.00%EURCZK0.00%NOKJPY0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%CHFNOK0.00%USDMXN0.00%USDNOK0.00%USDPLN0.00%GAGUSD0.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%W10.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-0.36%ETHUSD+22.11%USDTUSD+0.02%XRPUSD+15.55%SOLUSD+15.78%TRXUSDT+0.46%ZECUSDT-0.01%DOGEUSD+20.76%XMRUSDT-2.44%LINKUSD+23.15%BCHUSDT+1.02%XLMUSD-1.73%UNIUSD+1.50%LTCUSD+17.32%SUIUSD-1.49%HBARUSDT-0.65%TONUSD+36.45%TAOUSDT+0.91%AAVEUSD-0.74%DOTUSDT-1.43%ICPUSDT-1.29%ONDOUSDT-0.76%WLDUSDT-3.10%ARBUSDT+0.08%JUPUSDT-2.64%ATOMUSDT+0.17%INJUSDT+2.64%STXUSDT-0.43%TIAUSDT-0.56%PYTHUSDT+5.34%FETUSDT-2.19%SEIUSDT-3.15%IMXUSDT-1.76%GRTUSDT-2.00%OPUSDT-1.73%IOTAUSDT-2.01%WIFUSDT-4.11%POLUSDT-0.02%AXSUSDT-1.91%EOSUSDT-3.12%FARTCOINUSDT-2.60%DYDXUSDT-3.01%GALAUSDT-2.36%ORDIUSDT-1.50%RONINUSDT-1.68%NOTUSDT-1.33%
CE

Cerus Corporation (CERS)

NASDAQ • Healthcare

$2.33
+$0.02 (+0.9%)
Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$2.31
Day Range$2.29 - $2.36
Avg. Volume (3M)1.7M
Market Cap$469.5M
52 Week Range
$1.38$3.47
Next EarningsIn 8 daysNov 2, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$57.4M100%
Gross Profitminus cost of goods$29.5M51%

In plain terms: out of every $100 in revenue, Cerus Corporation currently loses $5.

Fundamentals & Financials

Revenue (TTM)
$221.5M
Net Income (TTM)
-$6.7M
EPS (TTM)
-$0.036
ROA (TTM)
-3.31%
Current Ratio
1.83
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

0.0%Q1 2026-$0.01
+66.7%Q2 2026-$0.01
+25.0%Q3 2026-$0.01
Next

Nov 2

in 8 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Cerus Corporation (CERS) reports next on November 5, 2026. Wall Street is looking for consensus EPS of -$0.013 on revenue of $63.2 million. For trailing context, revenue grew +9.5% year over year last quarter. Cerus has beaten EPS in 4 of 8 most recent quarters, making consensus alignment a key watch.

View full earnings history

About Cerus Corporation

Cerus Corporation develops and sells blood-safety technologies and related blood products in the medical device field. Listed on the NASDAQ as CERS, the company centers its business on the INTERCEPT Blood System for transfusable blood components and generated $206.1 million in FY2025 revenue.

Name
Cerus Corporation
CEO
Vivek K. Jayaraman
Website
www.cerus.com
Industry
Healthcare
Year Founded
1991
Employees
268

Today's Snapshot

AI-generated

CERS closed 0.9% higher at 2.33, outperforming a weaker sector. Earnings are due from CERS on 2 November.

Trading Volume

Below 10d avg (1.9M)

1.7M

vs S&P 500 Today

Outperforming Market

+1.39%

Updated: October 23, 2026 at 20:11 UTC

Technical Indicators

1 Buy3 Neutral4 Sell
CERS is changing hands around 2.33 with a mixed but ultimately negative technical profile: short-term SMAs/EMAs sit around the current price while medium- and longer-term averages lie above it, suggesting the recent strength is not yet broad-based. Momentum and MACD are effectively neutral to slightly negative, and ADX near 25 indicates trend pressure to the downside. Volatility is subdued given a small ATR, and volume metrics are conflicted—OBV looks constructive despite the broader moving-average alignment against the market. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$2.30 - $2.51
    Sell
  • RSI (14)46.71
    Neutral
  • Stochastic %K (14, 3, 3)77.01
    Neutral
  • MACD Level (12, 26)-0.06
    Neutral

Peers & Related Assets

HAEHaemonetics Corporation
$118.51+2.0%
ADMAADMA Biologics, Inc.
$10.68-2.5%
GRFSGrifols, S.A.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.